Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US

Dr. Reddy’s Laboratories, along with its subsidiaries, announced it has entered into a licensing agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify in United States. Lumify (Bausch + Lomb) is an over-the-counter (OTC) eye drop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the US.

Slayback Pharma is the first company to file an abbreviated new drug application for the private label equivalent for Lumify with the FDA under Paragraph IV certification. The abbreviated NDA is currently under FDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.

“We are pleased to license this important OTC ophthalmic product for the U.S. market,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s, said in a company news release. “This product complements Dr. Reddy’s growing OTC product portfolio in the eye care category that includes the private label versions of Pataday Once Daily Relief and Pataday Twice Daily Relief.”